alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2016475EN.01001601.xml

| 19.12.2016 | EN | Official Journal of the European Union | C 475/16 |
| --- | --- | --- | --- |

19.12.2016

EN

Official Journal of the European Union

C 475/16

---

Order of the General Court of 6 September 2016 — Vanbreda Risk & Benefits v Commission

(Case T-199/14) (1)

1

((Non-contractual liability - Public service contracts - Agreement on the amounts of compensation calculated in respect of loss - No need to adjudicate - Costs))

(2016/C 475/25)

Language of the case: French

Parties

Parties

Applicant: Vanbreda Risk & Benefits (Antwerp, Belgium) (represented: initially by P. Teerlinck and P. de Bandt, and subsequently by P. Teerlinck, P. de Bandt and R. Gherghinaru, lawyers)

Applicant:

Defendant: European Commission (represented: initially by S. Delaude and L. Cappelletti, and subsequently by S. Delaude, acting as Agents)

Defendant:

Re:

Re:

Application, first, for annulment of the decision of 30 January 2014 by which the Commission rejected the tender submitted by the applicant for Lot No 1 in the call for tenders OIB.DR.2/PO/2013/062/591, relating to insurance cover for property and persons (OJ 2013/S 155-269617), and awarded that lot to another company and, second, for damages.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate on the action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the action.

| 2. | The European Commission shall bear its own costs and pay the costs of Vanbreda Risk & Benefits incurred in the main proceedings and in the proceedings for interim measures before the General Court. |
| --- | --- |

2.

The European Commission shall bear its own costs and pay the costs of Vanbreda Risk & Benefits incurred in the main proceedings and in the proceedings for interim measures before the General Court.

---

(1)  OJ C 159, 26.5.2014.

1

---
Independent Auditors' Consent



The Board of Directors
Charter Financial, Inc.
Sparta, Illinois:

We consent to  incorporation  by reference in the  registration  statement  (No.
333-20173) on Form S-8 of Charter  Financial,  Inc. of our report dated November
3, 1997, relating to the consolidated balance sheets of Charter Financial,  Inc.
and subsidiary as of September 30, 1997 and 1996,  and the related  consolidated
statements of income, stockholders' equity, and cash flows for each of the years
in the three-year  period ended September 30, 1997, which report is incorporated
by reference  in the  September  30, 1997 annual  report on Form 10-K of Charter
Financial, Inc.

                                                       /s/KPMG Peat Marwick, LLP
                                                       -------------------------
                                                          KPMG Peat Marwick, LLP

St. Louis, Missouri
December 29, 1997
# C_2015056EN.01000801.xml

| 16.2.2015 | EN | Official Journal of the European Union | C 56/8 |
| --- | --- | --- | --- |

16.2.2015

EN

Official Journal of the European Union

C 56/8

---

Request for a preliminary ruling from the Højesteret (Denmark) lodged on 2 December 2014 — Finn Frogne A/S v Rigspolitiet ved Center for Beredskabskommunikation

(Case C-549/14)

(2015/C 056/10)

Language of the case: Danish

Referring court

Referring court

Højesteret

Parties to the main proceedings

Parties to the main proceedings

Applicant: Finn Frogne A/S

Applicant:

Defendant: Rigspolitiet ved Center for Beredskabskommunikation

Defendant:

Question referred

Question referred

Is Article 2 of Directive 2004/18/EC (1) of the European Parliament and of the Council of 31 March 2004 on the coordination of procedures for the award of public works contracts, public supply contracts and public service contracts, read in conjunction with the judgments of the Court of Justice of the European Union in Pressetext Nachrichtenagentur v Austria, C-454/06, ECR, ECLI:EU:C:2008:351, and Wall v La ville de Francfort-sur-le-Main and Frankfurter Entsorgungs- und Service (FES), C-91/08, ECR, ECLI:EU:C:2010:182, to be interpreted as meaning that a settlement agreement which introduces limitations on and amendments to the services to be provided as originally agreed by the parties under a contract previously put out to tender and also mutual agreement to waive application of remedies for breach in order to avoid a subsequent litigation constitutes a contract which in itself requires a tendering procedure, in a situation where the original contract has become distressed?

1

Pressetext Nachrichtenagentur

Austria

Wall

La ville de Francfort-sur-le-Main and Frankfurter Entsorgungs- und Service (FES)

---

(1)  OJ 2004 L 134, p. 114.

1

---
Exhibit 31.1
 Certification
  1.
    
    I have reviewed this annual report on Form 10-K of AXS-One Inc.;2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;4.
    
    The registrants other certifying officer(s) and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
     5.
    
    The registrants other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrants auditors and the
audit committee of the registrants board of directors (or persons performing the equivalent
functions):
   Date:  April 30, 2009
    /s/ William P. LyonsWilliam P. LyonsChairman of the Board and
Chief Executive Officer
§ 520.100 Amprolium. ( a ) *Specifications.* ( 1 ) Each milliliter of solution contains 96 milligrams (mg) amprolium (9.6 percent solution).
( 2 ) Each gram of powder contains 200 mg amprolium (20 percent).
( b ) *Sponsors.* See sponsors in 510.600(c) of this chapter. ( 1 ) Nos. 016592 and 061133 for use of products described in paragraph (a) of this section as in paragraph (d) of this section.
( 2 ) No. 066104 for use of product described in paragraph (a)(1) of this section as in paragraph (d) of this section.
( 3 ) No. 051072 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section.
( c ) *Related tolerances.* See § 556.50 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Growing chickens, turkeys, and laying hens.* It is used in drinking water as follows: ( i ) *Amount.* Administer at the 0.012 percent level in drinking water as soon as coccidiosis is diagnosed and continue for 3 to 5 days (in severe outbreaks, give amprolium at the 0.024 percent level); continue with 0.006 percent amprolium-medicated water for an additional 1 to 2 weeks.
( ii ) *Indications for use.* For the treatment of coccidiosis.
( iii ) *Limitations.* Use as the sole source of amprolium.
( 2 ) *Calves.* Administer concentrate solution or soluble powder as a drench or in drinking water as follows: ( i ) *Indications for use and amounts* — ( A ) As an aid in the prevention of coccidiosis caused by *Eimeria bovis* and *E. zurnii*, administer 5 mg per kilogram (mg/kg) body weight for 21 days during periods of exposure or when experience indicates that coccidiosis is likely to be a hazard.
( B ) As an aid in the treatment of coccidiosis caused by *E. bovis* and *E. zurnii*, administer 10 mg/kg body weight for 5 days.
( ii ) *Limitations.* Withdraw 24 hours before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Use as the sole source of amprolium.
[71 FR 56346, Sept. 27, 2006, as amended at 72 FR 60551, Oct. 25, 2007; 73 FR 45611, Aug. 6, 2008; 73 FR 70276, Nov. 20, 2008; 74 FR 10484, Mar. 11, 2009; 76 FR 38554, July 1, 2011; 76 FR 40808, July 12, 2011; 78 FR 23, Jan. 2, 2013; 78 FR 17596, Mar. 22, 2013; 78 FR 57058, Sept. 17, 2013; 81 FR 22523, Apr. 18, 2016; 81 FR 59133, Aug. 29, 2016; 84 FR 8972, Mar. 13, 2019; 86 FR 13184, Mar. 8, 2021]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3720 *Streptococcus* spp. exoenzyme reagents. ( a ) *Identification. Streptococcus* spp. exoenzyme reagents are devices used to identify antibodies to *Streptococcus* spp. exoenzyme in serum. The identification aids in the diagnosis of disease caused by bacteria belonging to the genus *Streptococcus* and provides epidemiological information on these diseases. Pathogenic streptococci are associated with infections, such as sore throat, impetigo (an infection characterized by small pustules on the skin), urinary tract infections, rheumatic fever, and kidney disease.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 61 FR 1119, Jan. 16, 1996; 66 FR 38792, July 25, 2001]
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Ambassadors International, Inc. (the Company) on Form 10-K for the year ended December 31, 2005 as filed with
the Securities and Exchange Commission on the date hereof (the Report), the undersigned, Joseph J. Ueberroth, Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                        |  |  |  | 
|----------------------- |  |  |  | 
|/s/ Joseph J. Ueberroth |  |  |  | 
|Joseph J. Ueberroth     |  |  |  | 
|Chief Executive Officer |  |  |  | 
|March 9, 2006           |  |  |  | 

The foregoing certification is being furnished solely to accompany this Report pursuant to 18 U.S.C.
§1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.
[LETTERHEAD OF WEINICK SANDERS LEVENTHAL & CO., LLP]
                          CERTIFIED PUBLIC ACCOUNTANTS

                 CONSENT OF WEINICK SANDERS LEVENTHAL & CO., LLP
                   (INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS)

We consent to the use in the Registration Statement of Atec Group, Inc. on Form
S-3 under the Securities Act of 1933 of our report dated August 18, 2000, except
for Note 13, as to which the date is September 18, 2000 and to the reference to
our firm under the heading "Experts" in the Prospectus.

                                        /s/ WEINICK SANDERS LEVENTHAL & CO., LLP

New York, New York
June 29, 2001
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

IN THE INTEREST OF: R.H.R.J., A

MINOR

PETITION OF: S.J., MOTHER

:

:

:

:

:

No. 401 EAL 2014

Petition for Allowance of Appeal from the

Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 30th day of September, 2014, the Petition for Allowance of

Appeal is DENIED.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsSynthesis and Thermal Conductivity of Exfoliated Hexagonal Boron Nitride/Alumina Ceramic CompositeExfoliated hexagonal boron nitride (hBN)/alumina composite can be fabricated by following the process of (1) heating a mixture of hBN, AlCl3, and NaF in nitrogen for intercalation; (2) heating the intercalated product in air for exfoliation and at the same time converting the intercalate (AlCl3) into Al2O3, (3) rinsing the oxidized product, (4) coating individual exfoliated hBN platelets that contain Al2O3 with new layers of aluminum oxide, and finally, (5) hot pressing the product into the composite. The composite thus obtained has a composition of approximately 60 percent by weight  hBN and 40 percent by weight  alumina. Its in-plane and through-plane thermal conductivity were measured to be 86 and 18 watts per meter Kelvin, respectively, at room temperature.Document ID20170003135Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsHung, Ching-cheh*(NASA Glenn Research Center Cleveland, OH, United States)*Hurst, Janet*(NASA Glenn Research Center Cleveland, OH, United States)*Santiago, Diana*(NASA Glenn Research Center Cleveland, OH, United States)*Lizcano, Maricela*(NASA Glenn Research Center Cleveland, OH, United States)*Kelly, Marisabel*(NASA Glenn Research Center Cleveland, OH, United States)*Date AcquiredApril 7, 2017Publication DateApril 1, 2017Subject CategoryComposite MaterialsFluid Mechanics And ThermodynamicsReport/Patent NumberNASA/TM-2017-219472GRC-E-DAA-TN39140E-19345Funding Number(s)WBS: WBS 081876.02.03.05.02.04Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType20170003135.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Exhibit 32.1

# Written Statement of
the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C.
§1350

Solely
for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, we, the undersigned President and Chief Executive
Officer and Vice President Law/Finance and Secretary of Ladish Co., Inc. (the
Company), hereby certify, based on our knowledge, that the Report on Form 10-Q
of the Company for the quarter ended September 30, 2007 (the Report)
fully complies with the requirements of Section 13(a) of the Securities Exchange Act of
1934 and that information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

/s/ Kerry L. Woody  Kerry L. Woody
President and Chief
Executive Officer

/s/ Wayne E. Larsen  Wayne E. Larsen
Vice President
Law/Finance & Secretary

October 31, 2007
# C_2014462EN.01001102.xml

| 22.12.2014 | EN | Official Journal of the European Union | C 462/11 |
| --- | --- | --- | --- |

22.12.2014

EN

Official Journal of the European Union

C 462/11

---

Appeal brought on 21 March 2014 by Firma Handlowa Faktor B. i W. Gęsina and Gęsina Wojciech against the order of the General Court (Second Chamber) of 22 January 2014 in Case T-468/12, Faktor B. i W. Gęsina v Commission

(Case C-138/14 P)

(2014/C 462/18)

Language of the case: Polish

Parties

Parties

Appellant: Firma Handlowa Faktor B. i W. Gęsina and Gęsina Wojciech (represented by: H. Mackiewicz, adwocat)

Appellant:

Other party to the proceedings: European Commission

Other party to the proceedings:

By order of 30 September 2014, the Court of Justice (Eighth Chamber) dismissed the appeal and ordered Firma Handlowa Faktor B. i W. Gęsina und Gęsina Wojciech to bear its own costs.

---
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access topublications in the archive is available through GPO's suite of cataloging andlocator services, including the Catalog of U.S. Government Publications(CGP).  Archived copies of publications are retrieved in the event thatpublications are no longer available from the original publishing agency site. 
**Title:**TheU.S. Army in the Iraq War
 
v.1|v.2|
 
SuDoc Number:D 101.146:IR 1/7/V.1-2
Item Number:0307-A-31 (online)
System Number: 001100207
July 16, 2019
Exhibit 23


graphic
              
              12400
      COIT ROAD
                SUITE
      1000
                DALLAS,
      TEXAS 75251-2005
                214/346-5800
      Fax: 214/346-5899
                E-mail:
      firm@philipvogel.com
 
 
   
 
 Consent of Independent
Auditors
 
 
  The Board
of Directors
 Preferred
Voice, Inc.
   We hereby
consent to the use in the Form 10-KSB filing of our report dated July 11, 2008,
relating to the balance sheet of Preferred Voice, Inc. as of March 31, 2008, and
the related statements of operations, changes in shareholders' equity, and cash
flows for the year ended March 31, 2008, which are contained in that
filing.
 
 
 Philip
      Vogel & Co. PCgraphic
 
 
 
 
 Dallas,
Texas
 
 July 11,
2008






































Members:
      American Institute of Certified Public Accountants • Texas Society of
      Certified Public AccountantsCPA
      Associates International, Inc. with Associated Offices in Principal U.S.
      and International Cities
#### Stephen B. Palmer III *v.*Hartford National Bank and Trust Company et al., Trustees (Estate of William N. Palmer) Carol R. Palmer et al. *v.*Hartford National Bank and Trust Company et al., Trustees (Estate of William N. Palmer)

King, C. J., Alcorn, House, Thim and Ryan, Js.

Argued December 10

decided December 11, 1968

*John C. Dennis,*for the appellants (defendants) in each case.

*James O. Shea,*for the appellees (plaintiffs) in each case.

Per Curiam.

The appeal in each case is dismissed for lack of jurisdiction in that the judgment appealed from is neither a complete nor a final judgment.
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8977]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3910]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel, Fellowships: Predoctoral Fellowships to Promote Diversity in 
Health-Related Research (DABP).
    Date: March 5, 2010.
    Time: 8 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Mandarin Oriental, 1330 Maryland Avenue, SW., Washington, 
DC 20024.
    Contact Person: Maribeth Champoux, PhD, Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 3170, MSC 7848, Bethesda, MD 
20892 301-594-3163, <a href="/cdn-cgi/l/email-protection#bfdcd7ded2cfd0cad2ffdccccd91d1d6d791d8d0c9"><span class="__cf_email__" data-cfemail="55363d3438253a2038153626277b3b3c3d7b323a23">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: February 18, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3910 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
#### § 520.540 Dexamethasone oral dosage forms.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3630 Methaqualone test system. ( a ) *Identification.* A methaqualone test system is a device intended to measure methaqualone, a hypnotic and sedative drug, in urine. Measurements obtained by this device are used in the diagnosis and treatment of methaqualone use or overdose.
( b ) *Classification.* Class II (special controls). A methaqualone test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
[52 FR 16122, May 1, 1987, as amended at 84 FR 71798, Dec. 30, 2019]
~ I